On Tuesday Bioline RX Ltd (NASDAQ:BLRX)’s shares enhanced 4.55%, and closed at $2.30, as the BioLineRx Ltd. a clinical-stage biopharmaceutical corporation dedicated to identifying, in-licensing and developing promising therapeutic candidates, declared recently successful top-line results from the Phase 1 safety and efficacy study of its lead clinical candidate, BL-8040, as a novel approach for mobilization and collection of bone-marrow stem cells from the peripheral blood circulation.
All safety and efficacy endpoints were met, showing that treatment with BL-8040 as a single agent was safe and well tolerated at all doses and resulted in efficient stem cell mobilization and collection in all study participants. Importantly, the results support BL-8040 as one-day, single-dose collection regimen, which is a noteworthyimprovement upon the current standard of care.
BioLineRx Ltd., a clinical stage biopharmaceutical development corporation, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs.
Informatica Corporation (NASDAQ:INFA)’s shares enhanced 4.28%, and closed at $47.79, hitting new 52-week high of $47.93, as the Informatica Corporation the world’s number one independent provider of enterprise data integration software and services, today announced that it has entered into a definitive agreement to be acquired by a company controlled by the Permira funds and Canada Pension Plan Investment Board (CPPIB) for approximately $5.3 billion.
Under the terms of the agreement, Informatica shareholders will receive $48.75 in cash for each share of Informatica common stock.
Informatica Corporation provides enterprise data integration software and services worldwide. Its enterprise data integration products include PowerCenter, PowerExchange, and Data Integration Hub, as well as PowerCenter Express, an entry-level data integration and profiling edition for departments or small to mid-market business, and cloud data integration solutions.
At the end of Tuesday’s trade, Twitter Inc (NYSE:TWTR), surged 3.99%, and closed at $52.87, as the Twitter spiked Tuesday as takeover rumors persist, making it TheStreet’s Move of the Day. Shares of the social network were on the move after rumors began to spread that two separate parties were interested in a takeover.
Twitter has statedly hired Goldman Sachs as an advisor after the two unnamed parties showed serious interest in an attainment, according to Barron’s. Twitter declined to comment. This isn’t the first time Twitter has been the subject of takeover talk.
As recently as January, shares surged on whispers activist investor Carl Icahn had taken interest in the corporation, though this was later proven false.
Twitter, Inc. operates as a global platform for public self-expression and conversation in real time. It offers various products and services for users, counting Twitter that allows users to create, distribute, and discover content; and Vine and video, a mobile application that enables users to create and distribute short looping videos.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), gained 3.90%, and closed at $4.53, as the Arena Pharmaceuticals, Inc. and Eisai Inc., declared that the US Patent and Trademark Office granted Arena US Patent No. 8,999,970, which describes a method for selecting appropriate patients based on renal function for BELVIQ® (lorcaserin HCl), a serotonin 2C receptor agonist approved for weight administration.
In addition to this method-of-treatment patent, composition of matter patents for BELVIQ are issued in major jurisdictions globally that, in most cases, are capable of ongoing into 2023. Arena has filed applications for patent term extension on patents directed to composition of matter in the United States, which, if granted, would extend the composition of matter patent term for BELVIQ into 2026 or potentially 2027.
Arena Pharmaceuticals, Inc., a biopharmaceutical corporation, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The corporation offers BELVIQ, a drug used to treat chronic weight administration in adults.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
